DSpace logo

Please use this identifier to cite or link to this item: http://142.54.178.187:9060/xmlui/handle/123456789/1492
Title: The safety and efficacy of biologic agents in treatment of systemic lupus erythematosus: A network meta-analysis
Authors: Tao, Meng-Jun
Cheng, Ping
Jin, Lai-Run
Zhou, Jun
Shi, Wei
Peng, Hul
Xu, Liang
Li, Zhi
Yuan, Hui
Keywords: Medical and Health Sciences
Atacicept
Belimumab
Biologic agents
Blisibimod
Epratuzumab
Network meta-analysis
Rituximab
Issue Date: 1-Jan-2019
Publisher: Pak J Med Sci
Abstract: Objective: Previous studies have shown that biologic agents out of the nine medicines might be beneficial for the treatment of SLE. The aim of this study was to evaluate the most effective medication of six biologic agents in treatment of SLE using network meta-analysis (NMA). The performance of these processes is ranked according to the results of this analysis. Methods: Multiple databases including PubMed, EMBASE and Cochrane Library was used to identify applicable articles and collect relevant data to analyzed by using STATA (13.0) software. The papers included in this study were divided into control group (placebo) and observation group (one of the six medicines). Results: A total of 21 eligible RCTs of biologic agents were identified, a total of 995 papers were included, and the results showed that the belimumab had the highest probability of being the most clinically efficacious intervention, with a surface under the cumulative ranking (SUCRA) curve of 75.0, was significantly superior (P < 0.05) to placebo alone. The blisibimod was the worst, with a SUCRA value of 29.4. The other biologic agents (atacicept, blisibimod, epratuzumab, rituximab, tabalumab) were insignificantly superior (P > 0.05) to placebo alone. Conclusions: Belimumab had the highest probability of being the best treatment for SLE compared with the other biologic agents (atacicept, blisibimod, epratuzumab, rituximab, tabalumab). The other biologic agents indicated an insignificant difference in efficacy for the treatment of SLE compared with placebo.
URI: http://142.54.178.187:9060/xmlui/handle/123456789/1492
Appears in Collections:Journals

Files in This Item:
File Description SizeFormat 
327.htm129 BHTMLView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.